Brachytherapy provider Imagyn Medical Technologies has agreed to sell its minimal-access surgery (MAS) product lines to Conmed in a stock swap valued at approximately $29.7 million. The sale, which completes the firm's divestiture of its entire MAS product line, will allow the Irvine, CA-based firm to concentrate its efforts on the oncology and critical care markets, said chairman and CEO Charles Laverty.
By AuntMinnie.com staff writersJune 12, 2001
Related Reading
Imagyn buys Intl. Isotopes brachytherapy assets, May 1, 2001
Theragenics adds deal with Imagyn, September 22, 2000
Copyright © 2001 AuntMinnie.com